Description

Dosage form

Tablets of a flat-cylindrical shape with a score and a bevel, from white to almost white.

The flat side with scribble has the inscription MATERIA MEDICA, the other flat side has the inscription SUBETTA.

Structure

Active substances: antibodies to the C-terminal fragment of the beta subunit of the insulin receptor affinity purified - 0.006 g *, antibodies to endothelial NO synthase affinity purified - 0.006 g * Excipients: isomalt, crospovidone, magnesium stearate * are applied to isomalt as a mixture of three active substances water-alcohol dilutions of the substance, diluted 10012, 10030, 100200 times, respectively.

pharmachologic effect

Antibodies to the C-terminal fragment of the β-subunit through the mechanisms of allosteric modulation sensitize the insulin receptor, increase its sensitivity to both endogenous and injected insulin, which is accompanied by activation of the metabolism of insulin-dependent glucose.

It has been experimentally shown that antibodies to the β-subunit have a moderately pronounced hypoglycemic effect (decrease in fasting glycemia by 0.7-1.4 mmol / L), while long-term use was not accompanied by the development of such side effects as hypoglycemia, acidosis, increased body weight, hemostasis disorders and hematopoiesis.

Antibodies to endothelial NO-synthase increase the activity of endothelial NO-synthase, which is accompanied by an increase in the content of NO, which has an endothelioprotective effect, helps to reduce vascular reactivity, reduce vascular spasm, normalize blood pressure and improve peripheral microcirculation.

Antibodies to endothelial NO-synthase have a moderately pronounced psychotropic effect in the form of anti-anxiety, antiasthenic, vegetative-stabilizing effects.

With the combined use of the components in the complex drug Subetta, a synergistic effect on the sensitivity of somatic cells to insulin is observed - due to the nonspecific NO-dependent activation of intracellular signal transduction from the insulin receptor, which makes it possible to increase the effectiveness of insulin therapy, stabilize the doses used and reduce the risk of side effects.

The drug reduces the severity of diabetes complications: cardiovascular disorders, neuropathies, nephropathies.

Pharmacokinetics

The sensitivity of modern physicochemical methods of analysis (gas-liquid chromatography, high-performance liquid chromatography, chromatography-mass spectrometry) does not allow assessing the content of ultralow doses of antibodies in biological fluids, organs and tissues, which makes it technically impossible to study the pharmacokinetics of Subetta.

Side effects

Possible reactions of increased individual sensitivity to the components of the drug.

Influence on the ability to drive vehicles and mechanisms:

Subetta does not affect the ability to drive vehicles and other potentially dangerous mechanisms.

Indications

As part of the complex therapy of patients with diabetes mellitus in the presence of insulin resistance.

Contraindications

Increased individual sensitivity to drug components.

Drug interactions

No cases of incompatibility with other drugs have been registered to date.

Dosage

Inside.

At one time - 1 tablet (keep in the mouth until completely dissolved, not during meals).

The tablet should be kept in the mouth without swallowing until it is completely dissolved.

The frequency of admission is set by the doctor and can vary from 2 to 4 times a day, depending on the degree of diabetes compensation.

Overdose

In case of an accidental overdose, dyspeptic symptoms are possible due to the fillers included in the drug.

Storage conditions

The drug should be stored in a dark place, out of reach of children, at a temperature not exceeding 25 ° C.

Shelf life is 3 years.

Do not use after the expiration date.

Name ENG

SUBETTA

Clinical and pharmacological group

Hypoglycemic drug

ATX code

Other hypoglycemic drugs

Dosage

6mg + 6mg

Structure

Active substances: antibodies to the C-terminal fragment of the beta subunit of the insulin receptor affinity purified - 0.006 g *, antibodies to endothelial NO synthase affinity purified - 0.006 g * Excipients: isomalt, crospovidone, magnesium stearate * are applied to isomalt as a mixture of three active substances water-alcohol dilutions of the substance, diluted 10012, 10030, 100200 times, respectively.

Indications

As part of the complex therapy of patients with diabetes mellitus in the presence of insulin resistance.

Storage conditions and periods

In a dark place at a temperature not exceeding 25 degrees.

Expiration date: 3 years

INN / Active ingredient

antibodies to the C-terminal fragment of the beta subunit of the insulin receptor affinity purified, antibodies to endothelial NO synthase affinity purified

Contraindications

Increased individual sensitivity to drug components.

Age under 18.

Specifications